Cargando…

Melatonin ameliorates tau-related pathology via the miR-504-3p and CDK5 axis in Alzheimer’s disease

BACKGROUND: Intracellular accumulation of the microtubule-associated protein tau and its hyperphosphorylated forms is a key neuropathological feature of Alzheimer’s disease (AD). Melatonin has been shown to prevent tau hyperphosphorylation in cellular and animal models. However, the molecular mechan...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Dongmei, Lan, Guihua, Li, Ruomeng, Mei, Yingxue, Shui, Xindong, Gu, Xi, Wang, Long, Zhang, Tao, Gan, Chen-Ling, Xia, Yongfang, Hu, Li, Tian, Yuan, Zhang, Mi, Lee, Tae Ho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9082841/
https://www.ncbi.nlm.nih.gov/pubmed/35527277
http://dx.doi.org/10.1186/s40035-022-00302-4
_version_ 1784703291077165056
author Chen, Dongmei
Lan, Guihua
Li, Ruomeng
Mei, Yingxue
Shui, Xindong
Gu, Xi
Wang, Long
Zhang, Tao
Gan, Chen-Ling
Xia, Yongfang
Hu, Li
Tian, Yuan
Zhang, Mi
Lee, Tae Ho
author_facet Chen, Dongmei
Lan, Guihua
Li, Ruomeng
Mei, Yingxue
Shui, Xindong
Gu, Xi
Wang, Long
Zhang, Tao
Gan, Chen-Ling
Xia, Yongfang
Hu, Li
Tian, Yuan
Zhang, Mi
Lee, Tae Ho
author_sort Chen, Dongmei
collection PubMed
description BACKGROUND: Intracellular accumulation of the microtubule-associated protein tau and its hyperphosphorylated forms is a key neuropathological feature of Alzheimer’s disease (AD). Melatonin has been shown to prevent tau hyperphosphorylation in cellular and animal models. However, the molecular mechanisms by which melatonin attenuates tau hyperphosphorylation and tau-related pathologies are not fully understood. METHODS: Immunofluorescence, immunoblotting analysis and thioflavin-S staining were employed to examine the effects of early and late treatment of melatonin on tau-related pathology in hTau mice, in which nonmutated human tau is overexpressed on a mouse tau knockout background. High-throughput microRNA (miRNA) sequencing, quantitative RT-PCR, luciferase reporter assay and immunoblotting analysis were performed to determine the molecular mechanism. RESULTS: We found that both early and late treatment of melatonin efficiently decreased the phosphorylation of soluble and insoluble tau at sites related to AD. Moreover, melatonin significantly reduced the number of neurofibrillary tangles (NFTs) and attenuated neuronal loss in the cortex and hippocampus. Furthermore, using miRNA microarray analysis, we found that miR-504-3p expression was upregulated by melatonin in the hTau mice. The administration of miR-504-3p mimics dramatically decreased tau phosphorylation by targeting p39, an activator of the well-known tau kinase cyclin-dependent kinase 5 (CDK5). Compared with miR-504-3p mimics alone, co-treatment with miR-504-3p mimics and p39 failed to reduce tau hyperphosphorylation. CONCLUSIONS: Our results suggest for the first time that melatonin alleviates tau-related pathologies through upregulation of miR-504-3p expression by targeting the p39/CDK5 axis and provide novel insights into AD treatment strategies. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40035-022-00302-4.
format Online
Article
Text
id pubmed-9082841
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-90828412022-05-10 Melatonin ameliorates tau-related pathology via the miR-504-3p and CDK5 axis in Alzheimer’s disease Chen, Dongmei Lan, Guihua Li, Ruomeng Mei, Yingxue Shui, Xindong Gu, Xi Wang, Long Zhang, Tao Gan, Chen-Ling Xia, Yongfang Hu, Li Tian, Yuan Zhang, Mi Lee, Tae Ho Transl Neurodegener Research BACKGROUND: Intracellular accumulation of the microtubule-associated protein tau and its hyperphosphorylated forms is a key neuropathological feature of Alzheimer’s disease (AD). Melatonin has been shown to prevent tau hyperphosphorylation in cellular and animal models. However, the molecular mechanisms by which melatonin attenuates tau hyperphosphorylation and tau-related pathologies are not fully understood. METHODS: Immunofluorescence, immunoblotting analysis and thioflavin-S staining were employed to examine the effects of early and late treatment of melatonin on tau-related pathology in hTau mice, in which nonmutated human tau is overexpressed on a mouse tau knockout background. High-throughput microRNA (miRNA) sequencing, quantitative RT-PCR, luciferase reporter assay and immunoblotting analysis were performed to determine the molecular mechanism. RESULTS: We found that both early and late treatment of melatonin efficiently decreased the phosphorylation of soluble and insoluble tau at sites related to AD. Moreover, melatonin significantly reduced the number of neurofibrillary tangles (NFTs) and attenuated neuronal loss in the cortex and hippocampus. Furthermore, using miRNA microarray analysis, we found that miR-504-3p expression was upregulated by melatonin in the hTau mice. The administration of miR-504-3p mimics dramatically decreased tau phosphorylation by targeting p39, an activator of the well-known tau kinase cyclin-dependent kinase 5 (CDK5). Compared with miR-504-3p mimics alone, co-treatment with miR-504-3p mimics and p39 failed to reduce tau hyperphosphorylation. CONCLUSIONS: Our results suggest for the first time that melatonin alleviates tau-related pathologies through upregulation of miR-504-3p expression by targeting the p39/CDK5 axis and provide novel insights into AD treatment strategies. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40035-022-00302-4. BioMed Central 2022-05-09 /pmc/articles/PMC9082841/ /pubmed/35527277 http://dx.doi.org/10.1186/s40035-022-00302-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Chen, Dongmei
Lan, Guihua
Li, Ruomeng
Mei, Yingxue
Shui, Xindong
Gu, Xi
Wang, Long
Zhang, Tao
Gan, Chen-Ling
Xia, Yongfang
Hu, Li
Tian, Yuan
Zhang, Mi
Lee, Tae Ho
Melatonin ameliorates tau-related pathology via the miR-504-3p and CDK5 axis in Alzheimer’s disease
title Melatonin ameliorates tau-related pathology via the miR-504-3p and CDK5 axis in Alzheimer’s disease
title_full Melatonin ameliorates tau-related pathology via the miR-504-3p and CDK5 axis in Alzheimer’s disease
title_fullStr Melatonin ameliorates tau-related pathology via the miR-504-3p and CDK5 axis in Alzheimer’s disease
title_full_unstemmed Melatonin ameliorates tau-related pathology via the miR-504-3p and CDK5 axis in Alzheimer’s disease
title_short Melatonin ameliorates tau-related pathology via the miR-504-3p and CDK5 axis in Alzheimer’s disease
title_sort melatonin ameliorates tau-related pathology via the mir-504-3p and cdk5 axis in alzheimer’s disease
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9082841/
https://www.ncbi.nlm.nih.gov/pubmed/35527277
http://dx.doi.org/10.1186/s40035-022-00302-4
work_keys_str_mv AT chendongmei melatoninamelioratestaurelatedpathologyviathemir5043pandcdk5axisinalzheimersdisease
AT languihua melatoninamelioratestaurelatedpathologyviathemir5043pandcdk5axisinalzheimersdisease
AT liruomeng melatoninamelioratestaurelatedpathologyviathemir5043pandcdk5axisinalzheimersdisease
AT meiyingxue melatoninamelioratestaurelatedpathologyviathemir5043pandcdk5axisinalzheimersdisease
AT shuixindong melatoninamelioratestaurelatedpathologyviathemir5043pandcdk5axisinalzheimersdisease
AT guxi melatoninamelioratestaurelatedpathologyviathemir5043pandcdk5axisinalzheimersdisease
AT wanglong melatoninamelioratestaurelatedpathologyviathemir5043pandcdk5axisinalzheimersdisease
AT zhangtao melatoninamelioratestaurelatedpathologyviathemir5043pandcdk5axisinalzheimersdisease
AT ganchenling melatoninamelioratestaurelatedpathologyviathemir5043pandcdk5axisinalzheimersdisease
AT xiayongfang melatoninamelioratestaurelatedpathologyviathemir5043pandcdk5axisinalzheimersdisease
AT huli melatoninamelioratestaurelatedpathologyviathemir5043pandcdk5axisinalzheimersdisease
AT tianyuan melatoninamelioratestaurelatedpathologyviathemir5043pandcdk5axisinalzheimersdisease
AT zhangmi melatoninamelioratestaurelatedpathologyviathemir5043pandcdk5axisinalzheimersdisease
AT leetaeho melatoninamelioratestaurelatedpathologyviathemir5043pandcdk5axisinalzheimersdisease